Prithviraj Bose, MD | Authors

Articles

Data From the RESPONSE Studies Drive Ruxolitinib Use in Polycythemia Vera

January 27, 2021

The way I practice, personally, is that if they are older than 60 years, they are automatically high risk, and I will start hydroxyurea. In PV, being over 60 years and/or prior thrombosis automatically makes the patient high risk, so you should probably be starting a cytoreductive therapy.

A Study Exploring Sotatercept and Ruxolitinib in MPN-Associated Myelofibrosis and Anemia

January 17, 2018

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.